Peptide News Digest

#Pevifoscorvir

2 stories

Clinical Trials · View digest

Aligos Therapeutics EASL 2026 HBV Combination Data: ALG-170675 ASO Synergizes With Pevifoscorvir Sodium; 40% of HBeAg+ Patients Reach HBsAg Levels Qualifying for ASO Therapy at Week 48

Aligos Therapeutics presented additional EASL 2026 data on its chronic hepatitis B (HBV) combination strategy. An analog of ALG-170675, a potential best-in-class antisense oligonucleotide (ASO), demonstrated additive-to-synergistic effects when combined with ALG-001075 (the active parent moiety of pevifoscorvir sodium, a capsid assembly modulator). Separately, 40% of HBeAg-positive chronic HBV patients treated with pevifoscorvir sodium for 48 weeks reached HBsAg reductions low enough to potentially qualify for ASO treatment — supporting a sequencing strategy toward functional HBV cure where the capsid modulator lowers viral antigen load before the ASO finishes the job. The data complements the ALG-055009 THR-β MASH results (46.2% liver-fat reduction) Aligos presented earlier in the week. The combination-and-sequencing approach mirrors the broader trend in liver disease toward layered mechanisms rather than single-agent therapy, and positions Aligos across the HBV, HDV, and MASH liver-disease franchises.

Clinical Trials · View digest

Aligos Therapeutics EASL 2026 Ten-Presentation Slate: ALG-055009 THR-β Agonist Hits 46.2% Placebo-Adjusted Liver-Fat Reduction at Week 12; Pevifoscorvir Sodium Reduces HBV cccDNA Reservoir

Aligos Therapeutics presented positive data across ten presentations at EASL 2026 Barcelona. The headline MASH data: ALG-055009, a THR-β (thyroid hormone receptor beta) agonist small molecule, met its primary endpoint in the Phase 2a HERALD study with robust liver-fat reduction at week 12 — doses of 0.5 mg to 0.9 mg achieving statistically significant reductions with placebo-adjusted median relative reductions up to 46.2% as measured by MRI-PDFF. On the viral hepatology side, Aligos presented Phase 1 data on pevifoscorvir sodium suggesting a reduced cccDNA reservoir in chronic HBV patients, with an investigator-led study showing ≥24-week follow-up in HBeAg+ participants after 96 weeks of monotherapy. The combined slate spans the Aligos chronic HBV, HDV, MASH, and liver cancer pipeline. The ALG-055009 THR-β mechanism puts Aligos in direct competition with Madrigal's Rezdiffra (resmetirom), the only FDA-approved MASH therapy, on the same receptor target.